Spike Gene Evolution and Immune Escape Mutations in Patients with Mild or Moderate Forms of COVID-19 and Treated with Monoclonal Antibodies Therapies.
Aged
Antibodies, Monoclonal
/ therapeutic use
Antibodies, Monoclonal, Humanized
/ therapeutic use
Antibodies, Neutralizing
/ therapeutic use
COVID-19
/ immunology
Drug Combinations
Evolution, Molecular
Female
Humans
Immune Evasion
Immunotherapy
/ statistics & numerical data
Male
Middle Aged
Mutation
SARS-CoV-2
/ genetics
Spike Glycoprotein, Coronavirus
/ genetics
COVID-19
Q493R
SARS-CoV-2
immune escape mutation
monoclonal antibodies therapy
spike gene
Journal
Viruses
ISSN: 1999-4915
Titre abrégé: Viruses
Pays: Switzerland
ID NLM: 101509722
Informations de publication
Date de publication:
24 01 2022
24 01 2022
Historique:
received:
04
01
2022
revised:
19
01
2022
accepted:
21
01
2022
entrez:
26
2
2022
pubmed:
27
2
2022
medline:
11
3
2022
Statut:
epublish
Résumé
We explored the molecular evolution of the spike gene after the administration of anti-spike monoclonal antibodies in patients with mild or moderate forms of COVID-19. Four out of the 13 patients acquired a mutation during follow-up; two mutations (G1204E and E406G) appeared as a mixture without clinical impact, while the Q493R mutation emerged in two patients (one receiving bamlanivimab and one receiving bamlanivimab/etesevimab) with fatal outcomes. Careful virological monitoring of patients treated with mAbs should be performed, especially in immunosuppressed patients.
Identifiants
pubmed: 35215820
pii: v14020226
doi: 10.3390/v14020226
pmc: PMC8877338
pii:
doi:
Substances chimiques
Antibodies, Monoclonal
0
Antibodies, Monoclonal, Humanized
0
Antibodies, Neutralizing
0
Drug Combinations
0
Spike Glycoprotein, Coronavirus
0
bamlanivimab and etesevimab drug combination
0
spike protein, SARS-CoV-2
0
bamlanivimab
45I6OFJ8QH
etesevimab
N7Q9NLF11I
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Agence Nationale de recherche sur le 232 SIDA et les hépatites virales - Maladies infectieuses émergentes
ID : Not applicable
Organisme : consortium EMERGEN
ID : Not applicable
Références
Nature. 2021 Dec 21;:
pubmed: 34937889
Elife. 2020 Oct 28;9:
pubmed: 33112236
Clin Microbiol Infect. 2022 Jan;28(1):139.e5-139.e8
pubmed: 34537363
Ann Oncol. 2021 Nov;32(11):1445-1447
pubmed: 34352377
Lancet. 2020 Mar 28;395(10229):1054-1062
pubmed: 32171076
Lancet. 2020 May 16;395(10236):1569-1578
pubmed: 32423584
Lancet Reg Health Eur. 2021 Sep;8:100164
pubmed: 34278371
Science. 2020 Aug 21;369(6506):1014-1018
pubmed: 32540904
Emerg Infect Dis. 2021 Oct;27(10):2728-2731
pubmed: 34314668
N Engl J Med. 2021 Oct 7;385(15):1382-1392
pubmed: 34260849
J Hepatol. 2021 Aug;75(2):435-438
pubmed: 33892006
N Engl J Med. 2021 Jan 7;384(1):20-30
pubmed: 33332779
N Engl J Med. 2021 Mar 18;384(11):1015-1027
pubmed: 33523609
Clin Infect Dis. 2021 Jun 24;:
pubmed: 34166499
J Infect. 2022 Feb;84(2):248-288
pubmed: 34437928
N Engl J Med. 2020 Nov 5;383(19):1813-1826
pubmed: 32445440